AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
AstraZeneca in AI collaboration with Immunai to inform cancer drug trials
AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)
AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team.
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca possesses all the key qualities of a qualitative dividend stock. The company topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. AstraZeneca boasts a balance sheet that's A-rated by S&P.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of breast cancer lived.
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca falls to five-month low on breast cancer trial results
AstraZeneca PLC (LSE:AZN) shares fell to a five-month low after it confirmed that another failed cancer trial of its Dato-DXd drug. The largest company in the FTSE 100 said it will continue to talk to regulators despite Phase III trial results of datopotamab deruxtecan (Dato-DXd) on patients with late-stage breast cancer showed it “did not achieve statistical significance”, ie help survival rates, compared to typical chemotherapy treatment.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themselves.
